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Background: Germline mutations in BRCA1 or BRCA2 lead to a high lifetime probability of developing ovarian or
breast cancer. These genes can also be involved in the development of non-hereditary tumours as somatic BRCA1/2
pathogenic variants are found in some of these cancers. Since patients with somatic BRCA pathogenic variants may
benefit from treatment with poly ADP ribose polymerase inhibitors, it is important to be able to test for somatic
changes in routinely available tumour samples. Such samples are typically formalin-fixed paraffin-embedded (FFPE)
tissue, where the extracted DNA tends to be highly fragmented and of limited quantity, making analysis of large
genes such as BRCA1 and BRCA2 challenging. This is made more difficult as somatic changes may be evident in only
part of the sample, due to the presence of normal tissue.
Methods: We examined the feasibility of analysing DNA extracted from FFPE ovarian and breast tumour tissue to
identify significant DNA variants in BRCA1/ BRCA2 using next generation sequencing methods that were sensitive
enough to detect low level mutations, multiplexed to reduce the amount of DNA required and had short amplicon
design. The utility of two GeneRead DNAseq Targeted Exon Enrichment Panels with different designs targeting only
BRCA1/2 exons, and the Ion AmpliSeq BRCA community panel, followed by library preparation and adaptor ligation
using the TruSeq DNA PCR-Free HT Sample Preparation Kit and NGS analysis on the MiSeq were investigated.
Results: Using the GeneRead method, we successfully analysed over 76% of samples, with >95% coverage of
BRCA1/2 coding regions and a mean average read depth of >1000-fold. All mutations identified were confirmed
where possible by Sanger sequencing or replication to eliminate the risk of false positive results due to artefacts
within FFPE material. Admixture experiments demonstrated that BRCA1/2 variants could be detected if present in
>10% of the sample. A sample subset was evaluated using the Ion AmpliSeq BRCA panel, achieving >99% coverage
and sufficient read depth for a proportion of the samples.
Conclusions: Detection of BRCA1/2 variants in fixed tissue is feasible, and could be performed prospectively to
facilitate optimum treatment decisions for ovarian or breast cancer patients.* Correspondence: gillian.ellison@astrazeneca.com
1Personalised HealthCare and Biomarkers, Innovative Medicines and Early
Development, AstraZeneca, Alderley Park, Macclesfield SK10 4TG, UK
Full list of author information is available at the end of the article
© 2015 Ellison et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Ellison et al. BMC Clinical Pathology  (2015) 15:5 Page 2 of 14Background
Mutations in the BRCA1 and BRCA2 genes lead to an
increased risk of developing breast or ovarian cancer as
part of hereditary breast-ovarian cancer syndrome.
Women who are heterozygous for a BRCA1 or BRCA2
pathogenic variant have up to an 80% risk of developing
breast cancer by age 90; and an ovarian cancer risk of
about 55% with BRCA1 mutations and 25% with BRCA2
mutations [1-4].
Researchers have established that these genes can also
be involved in the development of non-hereditary, spor-
adic tumours, as a proportion of ovarian and breast can-
cers contain somatic (tumour only) BRCA1 and BRCA2
pathogenic variants [5-15]. Patients with germline BRCA
mutations have been shown to derive a clinical benefit
from treatment with the poly ADP ribose polymerase
(PARP) inhibitor, olaparib [16]. As patients with tumours
that harbour a somatic BRCA mutation may also benefit
from treatment with PARP inhibitors, it is important to
be able to test for BRCA1 and BRCA2 variants in
tumour samples available after routine histopathology
assessment and diagnosis.
As the majority of clinical specimens are formalin-
fixed paraffin-embedded (FFPE) tissue, the subsequent
analysis of DNA extracted from such FFPE tumour sam-
ples is challenging. Clinical specimens may be small and
often yield a limited amount of low quality DNA, thus
constraining the analysis that can be undertaken. Unlike
the clinically relevant mutation spectrum of genes cur-
rently analysed on FFPE tumour DNA, such as KRAS or
EGFR, where the distribution and number of mutations
is small, thousands of clinically relevant variations in
BRCA1 and BRCA2 have been described, and these are
distributed widely throughout multiple, large coding
regions and intron-exon boundaries [17]. This poses a
significant challenge with respect to the accurate detec-
tion, analysis time, characterisation and interpretation of
sequence variants in BRCA1 and BRCA2.
Tumour samples are histologically heterogeneous
[18,19], and tumour-specific DNA will contain varying
proportions of contaminating DNA from normal cells.
Consequently, methods for somatic mutation detection
have to be able to detect DNA changes that may be
present in a low proportion of the total DNA isolated
from the sample. Next Generation Sequencing (NGS)
methods have the potential to detect variants at low
admixture levels due to the clonal nature of the method
[20]; conversely, screening both BRCA genes using
methods such as Sanger DNA sequencing requires a
significant quantity of input DNA. NGS methods also
offer a way to reduce the amount of input DNA required,
as the NGS reactions can be highly multiplexed. NGS
therefore offers a potential solution to this challenging
type of analysis.In this study we examined the feasibility of analysing
ovarian and breast FFPE tumour tissue for significant
variants (pathogenic variants, suspected pathogenic
variants and variants of uncertain significance [VUS])
in BRCA1 and BRCA2 using pre-developed commercially
available multiplex PCR library preparation panels for
NGS, which had been designed with short amplicons to
accommodate fragmented DNA from FFPE tissue.
Methods
Samples
A total of 68 ovarian FFPE tumour samples were ana-
lysed; these comprised 64 serous carcinomas, 2 endome-
trioid adenocarcinomas and 2 NOS (not otherwise
specified) carcinomas. All samples were obtained from
Asterand (Detroit, MI, USA) where they underwent a
haematoxylin and eosin pathology review to confirm the
presence of tumour in the samples and estimate tumour
content. Thirty breast FFPE tumour samples, of unknown
subtype, were obtained from Nottingham University (UK).
Limited pathology information on the breast samples was
provided by the supplier. These samples were collected
with appropriate consents that had been reviewed and
approved by appropriate regulatory and ethical authorities
(further details can be found at Asterand.com and nuh-
rise.org/nottingham-health-science-biobank).
Control material used was derived from FFPE hu-
man tumour explants of known BRCA mutation status
(HBCX17 BRCA2 c.6033_6034del, p.(Ser2012GlnfsTer5);
HBCX10 BRCA2 c.9106C>T, p.(Gln3036Ter)); DNA from
unfixed human cell line samples previously characterised
by Sanger DNA sequencing (MDA-MB-436 BRCA1 c.
5277+1G>A (homozygote), Cal51 BRCA2 c.2957delA,
p.(Asn986llefsTer14) (heterozygote), HCC1937 BRCA1
c.5266dupC p.(Gln1756ProfsTer74) (homozygote) and
BT474 BRCA2 c.9281C>A p.(Ser3094Ter) (heterozy-
gote)); and high molecular weight human genomic DNA
(Roche) of unknown BRCA status. Cell line admixtures of
50%, 25% and 12.5% were prepared using the aforemen-
tioned cell lines to a final concentration of 4 ng/μL. For
the 50% admixtures, BRCA1 and BRCA2 mutants were
mixed in equal proportions (admix 1: MDA-MB-436/Cal51
and 3: HCC1937/BT474); for the 25% admixtures, the
genomic DNA (Roche) was added to an equal volume of an
aliquot of the 50% admix 1; and for the 12.5% admixture,
an aliquot of admix 3 was diluted 1:4 using the genomic
DNA.
DNA was extracted from a single 40 μm thick section
of each FFPE sample (ovarian tumour, breast tumour
and explants) using the QIAsymphony DSP DNA Mini
Kit (Qiagen, Hilden, Germany). The resulting DNA was
quantified and assessed for quality by quantitative PCR
(qPCR) using the Human Genomic DNA (hgDNA)
Quantification and QC Kit (KapaBiosystems, Anachem).
Ellison et al. BMC Clinical Pathology  (2015) 15:5 Page 3 of 14The ovarian samples were also quantified using a Nano-
drop UV spectrophotometer (ThermoScientific, Wilming-
ton, DE, USA). Breast samples were not quantified in this
way as the data was not useful. Cell lines were extracted
by Tepnel Pharma Services (Manchester, UK) using a pro-
prietary method and quantified by UV spectrophotometry.GeneRead V.1 & V.2 panels
Where the concentration of amplifiable DNA deter-
mined by the hgDNA Quantification and QC kit (129 bp
premix) was greater than 4 ng/μL, samples were nor-
malised to 4 ng/μL using TE buffer. Multiplex PCRs
were set up according to the manufacturer’s instruc-
tions. For samples where normalisation to 4 ng/μL was
possible, 20 ng (5 μL) of DNA was added to each of the
four plexes. Where the concentration of DNA was
below 4 ng/μL, 5 μL of DNA was added per plex. PCR
amplification conditions were as specified by the
manufacturer except for those samples where the input
DNA concentration was below 2 ng/μL, in which case
the number of PCR cycles was increased from 25 to 30.
The four PCR plexes for each sample were pooled and
purified using QIAquick PCR purification columns
(Qiagen) then 2 μL of purified product was diluted 20x
and quantified on a 2200 Tapestation (Agilent Technolo-
gies Inc., Santa Clara, CA, USA). After quantification,
samples were normalised where possible to 4.2 ng/μL
using EB buffer (Qiagen) in preparation for end repair
using the TruSeq PCR-Free protocol (Illumina, San Diego,
CA, USA).Ion Ampliseq BRCA1/2 community panel
Where possible, 10 ng of DNA as measured by qPCR at
129 bp, was added to each of the three plexes. For sam-
ples where the concentration was lower than 830 pg/μL,
12 μL of DNA was added (the maximum volume of
DNA that could be added to each plex). PCRs were
otherwise set up according to the manufacturer’s
instructions, with the exception that the number of PCR
cycles was increased from the recommended 22 to 25.
Immediately after amplification, PCR primers were
digested using FuPa reagent (LifeTechnologies, Carlsbad,
CA, USA). Successful amplification in each plex was
monitored by separating 2 μL of PCR product by 2%
agarose gel electrophoresis. For samples where no visible
PCR amplification was observed, the reactions were
repeated as above but with 30 cycles of PCR. The three
PCR plexes were then pooled and 2 μL of the pooled
product was diluted 20x and then quantified on a 2200
Tapestation (Agilent). After quantification, samples were
normalised where possible to 4.2 ng/μL using EB buffer
(Qiagen) in preparation for end repair using the TruSeq
PCR-Free protocol (Illumina).TruSeq PCR Free library preparation
A 60 μL aliquot of each purified pooled plex (250 ng for
those samples at 4.2 ng/μL) was end repaired, purified
with AmpureXP beads (Agencourt; Beckman Coulter),
adenylated, and adapters ligated according to the manu-
facturer’s (Illumina) protocol. After adapter ligation, the
libraries were cleaned up and size-selected to remove
adapter monomers and dimers using GeneRead (Qiagen)
size selection columns according to the manufacturer’s
protocol. The libraries were then quantified in triplicate
using the KAPA Library Quantification Kit (Kapa Biosys-
tems) after initial dilution of aliquots to 1:4000 and 1:8000
in EB buffer (Qiagen).
Library normalisation and MiSeq NGS analysis
After quantification, each sample-specific library was nor-
malised to 0.5nM by the addition of EB buffer (Qiagen).
Samples at lower than 0.5nM concentration were left
undiluted. Twenty-four samples per NGS MiSeq run were
pooled in equal volumes and then denatured with an
equal volume of 0.2 N NaOH; they were then neutralised
with an equal volume of 200 mM Tris pH 7.0, giving a
library concentration of approximately 125pM. Prior to
loading on the MiSeq (Illumina), the pooled libraries were
diluted to a final concentration of 12.5pM with chilled
HT1 solution (Illumina). A 594 μL aliquot of the pooled
libraries in HT1 solution was then combined with 6 μL of
a 12.5pM PhiX control library and the 600 μL sample
loaded on to a MiSeq V.2 300 cycle reagent cartridge
and run on a MiSeq using a 2 × 150 bp paired end
configuration.
Bioinformatic analysis
Analysis of deep targeted data and accurate calling of
variants (particularly insertions/deletions) remains an
evolving field. A best practice pipeline based on the
bcbio-nextgen framework [21] was utilised for the pro-
cessing and analysis of all data. All raw sequence data
were processed from fastq files to variant calls using the
tools available through bcbio-nextgen. More specifically,
BWA-MEM [22] was chosen as the aligner within
bcbio-nextgen, and variant calling was performed using
an ensemble calling methodology, which combined indi-
vidual variant calls produced by FreeBayes [23], GATK
Unified Genotyper and GATK Haplotype Caller [24].
These variant callers are most suitable for germline vari-
ant analysis, namely for summarising differences be-
tween the data and the reference genome. However, as
no matched normals were analysed and there are no ma-
ture, best practice pipelines for tumour-only analysis, it
was decided to utilise these mature best practice germ-
line variant calling pipelines for variant detection here.
Data for visualising the differences in the amplicon
coverage was extracted from the alignment BAM files by
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the alignment BAM files was performed using a custom
Python program, which assigns each aligned short read
to the amplicon with most overlap to a designed ampli-
con, and soft clips any bases residing outside the ampli-
cons. This was performed as the reference-matching
primers of certain amplicons were diluting the allele
frequencies of variants observed within overlapping true
amplicons. A second pass of variant calling and coverage
estimation was performed on the trimmed alignment
files. In all cases variant detection frequencies quoted in
this paper represent the outputs from the primer trimmed
results unless stated otherwise.
High confidence BRCA1/2 variants were classified
through interrogation of publicly available data. Vari-
ants initially classified as pathogenic mutations, likely
pathogenic mutations or VUS, were confirmed by ei-
ther Sanger DNA sequencing and/or repeat NGS start-
ing from the original sample. Where a result could not
be confirmed it was regarded as an artefact.
Sanger DNA sequencing
Where possible high confidence variants were confirmed
by Sanger sequencing. PCR primers were designed using
the Primer 3 program (http://primer3.ut.ee/) with default
settings and the ‘Human’ mispriming library setting se-
lected. Amplicons for Sanger sequencing were designed to
be <150 bp in size in order to robustly amplify fragmented
DNA with the variant in the central third of the amplicon.
PCR primer sequences were checked to ensure that they
did not overlie any SNP variants and hence be subject
to amplification failure using the NGRL diagnostic
SNP check tool (https://secure.ngrl.org.uk/SNPCheck/).
Primers were synthesized at 50nM scale and cartridge
purified (Sigma-Aldrich). Primer sequences are in
Additional file 1.
PCR amplification was carried out using Promega
GoTaq® PCR mix with each primer at 500nM concentra-
tion under standard conditions with 30 PCR cycles and
55°C annealing. PCR amplifications were all carried out
in duplicate alongside a known normal control cell line
sample. Successful PCRs were purified prior to sequen-
cing using Agencourt® AmpureXP® beads according to
the manufacturer’s protocol. Purified PCR products were
Sanger sequenced in both forward and reverse orienta-
tions using the same primer sequences used for PCR at
200nM final concentration using BigDye® v3.1 according
to manufacturer’s cycling conditions. BigDye® v3.1 se-
quencing reactions were then purified using Agencourt®
CleanSeq® beads according to the manufacturer’s protocol
and analysed on an Applied Biosystems 3730xl. Sanger se-
quencing data was analysed alongside the normal control
cell line data for the presence of mutations using Mutation
Surveyor® software (SoftGenetics).Results
DNA input
Although the IonAmpliSeq panel recommended using
qPCR for DNA quantification, and the GeneRead panel
recommended a spectrophotometric method (Nanodrop),
from previous experience of analysing DNA extracted
from FFPE material [26], which is typically degraded, we
were aware that qPCR was a superior method of estimat-
ing amplifiable DNA (DNA of sufficient length to amplify
in a PCR reaction) than UV spectrophotometry. The
hgDNA Quantification and QC Kit (KapaBiosystems) was
therefore selected to perform qPCR and to quantitate the
DNA from the FFPE samples. This method used ampli-
cons of 3 different sizes (41 bp, 129 bp and 305 bp) to esti-
mate the quantity and integrity of amplifiable DNA. We
found that ovarian tumour samples contained similar
quantities of DNA amplifiable by the 41 bp and 129 bp
amplicons, whereas breast samples showed a higher value
of the 41 bp compared with 129 bp products, suggesting
that DNA isolated from breast samples was more de-
graded. Both sample types showed considerable deterior-
ation in quantities of amplifiable DNA >129 bp, as the
305 bp amplicon generated much lower quantification
readings (Figure 1). The ovarian DNA samples were also
quantified using a Nanodrop, but these values were con-
siderably higher than qPCR and, in most cases, would
have resulted in a substantial overestimation of amplifiable
DNA input into the assays (Figure 1). We therefore did
not quantify the breast panel in this way to conserve
DNA. The 129 bp product was selected to determine the
amount of DNA to add into the BRCA panel, as it was the
closest measure to the mean amplicon size of all methods
being evaluated (GeneRead V.1: 155 bp (estimated), V.2:
153 bp, Ion AmpliSeq ~197 bp).
Comparison of BRCA panel specifications
The BRCA panels varied in their specifications, such
as the amount of input DNA required; the number of
multiplexes; and the gene coverage (Table 1). Before
selecting the most appropriate method, however, it was
important to test some of these factors empirically to
ensure that they fulfilled the claims on typical clinical
samples using the equipment available to the laboratory.
GeneRead V.1 (Qiagen)
There were gaps in the coverage of the coding sequences
of both BRCA genes due to assay design. The theoretical
maximum coverage of BRCA1 and BRCA2 (excluding
untranslated regions [UTRs], but including 2 bp intron-
exon boundaries) was approximately 97.0%. In BRCA1,
the design coverage was 98.7% with the first 25 bp of
coding exon 1 and 42 bp in coding exon 7 omitted as
well as some intron-exon boundaries totalling 66 bp of


































Figure 1 Comparison of DNA concentration measurements. DNA quantification data generated by qPCR using 3 different amplicon sizes
(41 bp, 129 bp and 305 bp) for all samples studied, and Nanodrop readings for ovarian samples only. The data indicate the level of degradation
of DNA in each sample. Ovarian samples appeared to be less degraded than the breast samples as the 41 bp and 129 bp measurements were
more similar compared with the marked differential of nearly an order of magnitude observed for the breast samples. Nanodrop readings did not
appear to correlate with the qPCR data, generating significantly higher readings as a measure of total DNA rather than amplifiable DNA (ovarian
sample data only). Data have been plotted on a log scale to enable a visual comparison.
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8, 9, 10, 11, 12, 14, 15, 18, 19, 21 and 26 missed as well
as multiple exon-intron boundaries totaling 408 bp of
missed sequence. With this incomplete coverage, a re-
view of the Breast Cancer Information Core database
[27] suggested that around 5% of reported pathogenic
variants, if present in the samples, would be missed.
High molecular weight DNA extracted from human
cell lines and FFPE explant samples with pathogenic
BRCA mutations were used as control samples initially,
to determine if the GeneRead version1 (V.1) panel func-
tioned adequately. Although the explant samples had
been formalin-fixed and embedded in paraffin, the DNA
in these samples was not as degraded as the tumour
samples, as observed using qPCR. Some admixtures of
mutant cell line DNAs with normal control DNA sam-







GeneRead V.1 BRCA1/2 97% 276 155 (104)
GeneRead V.2 BRCA1/2 100% 237 153 (109)
Ion AmpliSeq BRCA1/2 100% 167 197 (145)
*The minimal target regions for 100% design coverage for this assessment was def
NM_00059.3), respectively, plus at least the 2 bp flanking each coding exon (canon
calculated as 5,680 bp and 10,361 bp for BRCA1 and BRCA2, respectively (total 16,04
intronic regions, these were not considered in this calculation.
+Amplicon size ranges are quoted as length with primer sequences, where known,limits of mutation detection. The GeneRead V.1 panel
generated adequate results with our protocol, with most
samples achieving >100x coverage for 97.0% of the se-
quence (the theoretical maximum coverage by design)
and a mean read depth of >3,900-fold. The exception
was one of two explant samples (HBCX17), which per-
formed slightly less well (93.8% coverage at 100x). All
the expected mutations were identified in the cell lines
and explant samples and none were found in the pre-
sumed negative control DNA sample. In admix 4, which
was a 12.5% mix of 2 different mutant cell lines in wild
type DNA, the BRCA2 c.9281C > A p.(Ser3094Ter) mu-
tation was not detected automatically by the analysis
pipeline, but was present on visual inspection of the
data. Since this admixture was derived from a hetero-
zygous mutant sample, in theory the mutant allele






(58–125) 4 80 ng total, 20 ng/pool
(determined by OD260)
105-200 (52–159) 4 80 ng total, 20 ng/pool
(determined by OD260)
126-298 (71–242) 3 30 ng total, 10 ng/pool
(determined by qPCR)
ined as 100% coverage of the BRCA1 and BRCA2 CDS (NM_007294.3 and
ical splice sites). The lengths of these features across the two genes were
1 bp). Although the designs in many cases covered sequence further into
and length without primer sequences in parentheses.
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2 and 3, demonstrated that on first inspection this
method was specific, and had the potential to have
sufficient limit of detection.
Assay performance was evaluated on typical clinical
material that varied in DNA yield, level of degradation
and percentages of neoplastic material. Twenty-two
percent (22/98) of all samples met the required DNA
amount as specified by the GeneRead protocol, and were
added at 20 ng per primer pool (4 pools to cover BRCA1
and BRCA2) following the standard protocol (25 PCR
cycles). For these samples, the theoretical maximum
coverage was achieved at a minimum depth of 100x and
with a mean depth of coverage exceeding 4,000x.
As the majority of samples (75/98) yielded less than the
recommended input DNA concentration, we evaluated
the assay performance on these lower DNA-yielding
samples to determine if usable data could be generated.
Where the DNA concentration was below half the rec-
ommended input (10 ng per pool), the number of PCR
cycles was extended to 30 to increase the yield of PCR
products. PCR efficiency was monitored initially by
agarose gel electrophoresis and then by Tapestation
(Agilent).
The majority of samples with low DNA yields pro-
duced adequate PCR products and sequencing data
without any significant deterioration in coverage or read
depth until less than 1 ng of amplifiable DNA was added
per primer pool (Figures 2 and 3). Of the 75 samples
with less than optimal DNA input, 32 samples still gen-
erated the maximum possible coverage of approximately
97%, and a further 20 samples generated a coverage of
>95% at a minimum read depth of 100x. The majority of
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Figure 2 Percentage coverage at 100x depth compared with DNA inp
DNA inputs. Approximately 97% coverage (maximum by design) is achieve
than 20 ng of DNA input per plex is used >95% coverage is still obtained f
per plex.which for tumour analysis is important in order to
identify low level somatic mutations with confidence.
Identification of significant variants
Eight samples with pathogenic variants and six samples
with VUSs in BRCA1 and BRCA2 were identified in the
98 clinical samples tested (Table 2) using the GeneRead
V.1 method. These were classified using a diagnostic
protocol, which follows professional guidelines adopted
in the UK for the interpretation of VUSs [28]. In brief,
the protocol integrates publicly available data from peer-
reviewed publications, databases and analysis with out-
put from in silico tools, and categorises the variant using
the 5-class system proposed by the IARC Unclassified
Genetic Variants Working Group [29]. Table 2 lists the
variants in classes 3, 4 & 5. As we did not have any
matched lymphocyte DNA for these patients we were
unable to determine if the BRCA mutations/variants
were germline or somatic events. Twelve of the fourteen
variants were confirmed by both repeat NGS and Sanger
DNA sequencing. One sample could not be confirmed
by Sanger DNA sequencing due to PCR failure, likely
due to the poor quality fragmented DNA from the FFPE
sample but was successfully confirmed on repeat NGS
analysis. Another sample could not be reanalysed by
NGS due to insufficient DNA remaining, but was con-
firmed by Sanger DNA sequencing.
Seven additional significant variants were identified
that could not be replicated or confirmed using an alter-
native method; these were considered to be PCR arte-
facts, which are known to occur when analysing DNA
extracted from FFPE tissue [26]. The majority of these
were in poor quality, low input DNA samples with lower























ut using GeneRead V.1. Gene coverage is shown over the range of
d when the recommended DNA input of 20 ng per plex is used. If less
or 70% (52/75) of samples even with as little as 1 ng input DNA
Figure 3 Heat map of GeneRead V.1 coverage and read depth over the range of DNA input. As DNA concentration becomes low the read
depths tend to become lower. Consistent gaps in the coverage were detected by observing the red continuous horizontal lines.
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of amplifiable DNA). Repeat analysis by NGS or Sanger
DNA sequencing enabled us to readily distinguish true
positives from artefacts, as artefacts did not replicate.
GeneRead V.1 extended evaluation
Input DNA
As we were unable to isolate DNA at the recommended
input concentration for a high proportion of FFPE
tumour samples, we examined the effect of decreasing
input DNA on test performance and ability to detect aTable 2 High impact variants
Sample Sample type High impact variant
AZ68+ Ovary BRCA1 c.1105delG p.(Asp369MetfsTer5)
AZ75+ Ovary BRCA1 c.1105delG p.(Asp369MetfsTer5)
AZ30 Ovary BRCA1 c.4675G>A p.(Glu1559Lys)
AZ28 Ovary BRCA1 c.5266dupC p.(Gln1756ProfsTer74)
AZ23 Ovary BRCA2 c.7007+1G>C
AZ11 Ovary BRCA1 c.181T >G p.(Cys61Gly)
AZ113 Breast BRCA1 c.2253_2254delGT p.(Met751IlefsTer10)
AZ109 Breast BRCA1 c.5095C>T p.(Arg1699Trp)
AZ17 Ovary BRCA1 c.2060A>C p.(Gln687Pro)
AZ78 Ovary BRCA2 c.1408G>C p.(Glu470Gln)
AZ72 Ovary BRCA2 c.10024G>A p.(Glu3342Lys)
AZ39 Ovary BRCA2 c.7788delAinsGGGT p.(Gly2596dup)
AZ29 Ovary BRCA2 c.9302 T>C p.(Leu3101Pro)
AZ10 Ovary BRCA2 c.10095delinsGAATTATATCT p.(Ser3366As
These variants were confirmed by repeat NGS and validated by Sanger DNA sequen
PCR failure, possibly due to the poor quality of the FFPE sample. Another sample w
+Samples AZ68 and AZ75 are thought to be separate samples from the same tumo
have exactly the same variant calls (including coding SNPs).variant. A FFPE tumour sample containing the BRCA2
c.10095delinsGAATTATATCT p.(Ser3366AsnfsTer4) vari-
ant was processed with a series of input DNA amounts
from the recommended 80 ng down to 2.5 ng DNA input
total (20 ng down to 0.6 ng DNA input per primer pool).
This range of inputs represented 90% of our sample set.
This sample series was included as part of a standard
analysis batch of 24 samples. The BRCA2 variant was
still detected using a DNA input/pool of 0.6 ng when
run in a standard batch of 24 samples (Additional file 4).






pathogenic 72 Yes Yes
pathogenic 68 Yes Yes
pathogenic 58 Yes Yes
pathogenic 52 Yes Yes
pathogenic 79 Yes Yes
pathogenic 84 Yes No data*
pathogenic 52 Yes Yes
pathogenic 59 Yes Yes
VUS 90 Yes Yes
VUS 76 Yes Yes
VUS 46 Yes Yes
VUS 58 Yes Yes
VUS 82 No data Yes
nfsTer4) VUS 100 Yes Yes
cing. One sample* could not be confirmed by Sanger DNA sequencing due to
as not reanalysed by NGS, but was confirmed by Sanger DNA sequencing.
ur block as they were sourced from the same supplier at the same time and
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percentage coverage at 100x depth was unaffected by the
range of input DNA quantities used. An analysis of four
single-nucleotide polymorphisms (SNPs) present in this
sample also showed the same consistency over the range
of DNA inputs (Additional file 5). This implies that if
DNA integrity is good, it is possible to generate reliable
results with much lower input DNA amounts than the
recommended amount, making analysis possible even in
FFPE tumour samples that yield low DNA amounts.
Limit of variant detection in a background of DNA
As none of the tumour samples were found to contain
a validated low frequency variant, we used a series of
decreasing variant content admixtures as a model system
to assess the ability of the method to detect variants at
low proportions as could occur in a heterogeneous
tumour. Three FFPE tumour DNA samples known to
harbour BRCA pathogenic mutations were mixed with a
single background non-mutant FFPE tumour DNA to
make 1/2, 1/4, 1/8 and 1/16 admixtures. The total amplifi-
able input DNA remained constant at 80 ng per test
(20 ng per plex) (Admix set 1: BRCA2 c.10095delins-
GAATTATATCT p.(Ser3366AsnfsTer4); Admix set 2:
BRCA1 c.2060A>C p.(Gln687Pro); Admix set 3: BRCA2
c.7007+1G>C). All the variants were clearly detected in
the lowest 1/16 admixture (Table 3). Although the relative
numbers of reads with the variants declined with the
lower admixtures, the actual proportion was not always as
predicted and may indicate that the measure of amplifi-
able DNA at 129 bp qPCR is not fully reflecting the num-
bers of amplifiable copies of each BRCA locus in each
sample. Nevertheless, BRCA mutations could be readily
detected if present in >10% of a sample DNA, which
should enable the detection of low level mutationsTable 3 Detection of variants in decreasing proportions of th
















*Expected frequencies were based on results from a previous run where the samplecommonly found in tumour material. If the level of neo-
plastic cells is lower, macro or microdissection to enrich
for the proportion of tumour cells may be necessary to
achieve the required limit of detection although we did
not assess this in this study.
Reproducibility of analyses
To evaluate reproducibility, tumour samples that were
found to contain a significant mutation were replicated
in at least duplicate. In addition, 3 samples that did not
contain significant BRCA variants were chosen at ran-
dom, but with sufficient DNA to perform additional ana-
lysis, were also replicated. When the DNA input was at
the recommended amount the method was highly repro-
ducible, but when the DNA input decreased below 1 ng
per test, reproducibility deteriorated. Coverage was not
as consistent and non-reproducible artefacts were more
likely to occur in the lower DNA-yielding samples. Sam-
ples with artefacts were typically evaluated in triplicate
to verify the result (Figure 4).
GeneRead V.2 panel
As the GeneRead V.2 panel design was not available at
the start of the study, it was only possible to conduct a
limited evaluation. Twelve FFPE DNA samples from
ovarian tumours that had previously been analysed with
the GeneRead V.1 panel were re-analysed with the
modified (improved coverage) V.2 panel. The theoretical
maximum coverage of BRCA1 and BRCA2 (excluding
UTRs) was 100%, with no coverage gaps in either gene,
and all exon-intron boundaries covered. Eight of the
twelve samples selected were analysed using a total
DNA input of 80 ng at 129 bp (20 ng of DNA per plex).
The remaining four samples were of poorer quality and
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Figure 4 GeneRead V.1 reproducibility of analyses. Coverage at 100x depth was reproducible at the recommended DNA input, but as the
DNA amount fell below about 1 ng, data were less reproducible. At lower DNA input amounts, BRCA status was less reproducible. ++ positive in
all replicates (verified BRCA positive); −− negative in all replicates (negative); +−− positive in first analysis, negative in replicates (artefact - considered
negative); +F positive in 1 replicate, but no NGS result in the replicate.
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V.2 panel had previously yielded good coverage with the
V.1 panel at or very near to the maximum achievable
coverage (97%).
One of the twelve samples (AZ68) was an ovarian can-
cer sample where the pathogenic mutation BRCA1
c.1105delG p.(Asp369MetfsTer5) had been identified
and confirmed. This was also identified on the V.2 panel
analysis. No additional mutations were identified using
the V.2 panel.
The overall coverage at 100x minimum depth of the
V.2 panel was marginally superior to that obtained with
the V.1 panel (Additional file 6). Inspection of the data
revealed that although some areas of BRCA1 and
BRCA2 that had not previously been encompassed in
the design were now covered, other amplicons from re-
gions previously satisfactorily covered on V.1 were now
failing. Although coverage by design should have been
100%, the maximum achieved in this small evaluation
was 98.9% (Figure 5). The V.2 panel would benefit from
further optimisation to achieve 100% coverage. It should
be noted that V.1 PCR reagents were used in this small
evaluation and use of V.2 mastermix may improve the
performance but was not tested.
Ion AmpliSeq panel
A small evaluation of the Ion AmpliSeq panel was
conducted, although modification of the protocol was
required in order to conduct the analysis on the MiSeq
instrument. Twelve FFPE DNA samples from ovarian
tumours that had previously been analysed with the
GeneRead V.1 panel were analysed with the Ion AmpliSeq
panel. Eight samples were added to the assay at therecommended DNA input (30 ng) and 4 samples were
added at just below the recommended DNA input. For
optimisation purposes, one set of 12 samples was proc-
essed using 25 PCR cycles and a second set was processed
using 30 PCR cycles as preliminary results had shown
some poorly performing samples. Attainment of 100x
minimum coverage with the amplicons was variable in
this evaluation, including those samples where 30 ng at
129 bp of input DNA was available. Data generated from
25 PCR cycles generally gave better coverage and read
depth for the majority of samples but not in all cases
(Figure 6 and Additional file 7). The majority of the
poorly performing amplicons were in primer pool 3. We
investigated the possibility of whether this could be due
to primers, PCR amplicon size or GC content. However,
the average size of the primer pool 3 products was only
about 5 base pairs longer than in other pools, which we
did not think should have had such a notable effect, and
the GC content, length of primers and numbers of
primers were almost identical in all 3 pools.
A table summarising which samples were analysed
using which method can be found in the Additional file 8.
NGS data has been deposited in The European Nucleotide
Archive (www.ebi.ac.uk/ena): submission reference num-
ber PRJEB8503.
Discussion
BRCA1 and BRCA2 germline variant screening using
Sanger DNA sequencing or NGS is well established in
clinical practice and is used primarily for the determin-
ation of hereditary breast and ovarian cancer risk
[30-33]. The screening methods used are optimised for
good quality, high molecular weight input DNA of high
Read depth
AZ26
v1 v2 v1 v2 v1 v2 v1 v2 v1 v2 v1 v2 v1 v2 v1 v2 v1 v2 v1 v2 v1 v2 v1 v2






Figure 5 Comparison of GeneRead panels versions 1 and 2. Some areas of BRCA1 and BRCA2 that had not previously been encompassed in
the V.1 design were now covered, but other amplicons from regions previously satisfactorily covered on V.1 failed in the V.2 design.
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not readily translate to the analysis of FFPE tumour ma-
terial, where the extracted DNA is typically of poor qual-
ity, highly fragmented and of low yield [26]. In addition,
Sanger DNA sequencing methods may not be sensitive
enough to detect low level somatic changes and are
more expensive and difficult to scale for high throughput
applications than NGS assays [20]. With the advent of
treatment-focused BRCA testing and the potential of pa-
tients with somatic as well as germline BRCA pathogenic
or likely pathogenic variants in ovarian tumours to bene-
fit from PARP inhibitor therapy [16], there is an increas-
ing clinical need for routine BRCA screening of FFPEAZ10
25 30 25 30 25 30 25 30 25 30 25 30 2cycles
AZ26 AZ27 AZ28 AZ30 AZ34 A
Figure 6 Gene coverage and read depth using the Ion Ampliseq BRCA
generally better at 25 cycles for the majority of samples compared with 30
coverage regions.tumour DNA. Designing and clinically validating a NGS
BRCA assay for use on FFPE tissue could take consider-
able time, effort and cost. The use of pre-developed
BRCA panels allowed us to rapidly establish a protocol
for BRCA screening in DNA extracted from FFPE breast
and ovarian tumour tissue, and to ascertain the feasibil-
ity of routine BRCA tumour testing.
To be of clinical utility, any method needs to generate
usable results on as many typical FFPE samples as pos-
sible, often with low yields of DNA. During this investi-
gation we evaluated BRCA panel performances on a
range of DNA concentrations and sample quality, as
measured by qPCR over 3 amplicon sizes (41 bp, 129 bpRead depth
5 30 25 30 25 30 25 30 25 30 25 30






1/2 panel; effect of 25 and 30 PCR cycles. Depth of coverage was
cycles. Pool 3 products were responsible for the majority of low
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DNA input of 80 ng in total (20 ng per primer pool or
plex) and the Ion AmpliSeq BRCA panel an input of
30 ng (10 ng per primer pool). The qPCR reading at
129 bp was used to estimate DNA input as this was clos-
est in size to the range of amplicons in the panels. For
routine screening, it is likely we would only run a single
qPCR assay with a product size similar to the panel
product sizes for DNA estimation in order to conserve
DNA and reduce overall turnaround time. For this
evaluation, however, it was useful to have more informa-
tion on the quality and quantity of DNA to allow us to
develop the process. We found qPCR was a reliable
method for measuring the amount of input DNA to use,
and for predicting downstream assay success. When suf-
ficient DNA input as measured by the 129 bp amplicon
was added to the BRCA tests, the assays performed as
expected with maximum achievable coverage and suffi-
cient read depth.
Results generated using the GeneRead V.1 panel dem-
onstrated that close to the theoretical maximum cover-
age was achievable. This included those samples with as
little as 1 ng of amplifiable DNA per primer pool. An
average read depth of >1,000x was also attained for the
majority of samples. The GeneRead V.2 panel improved
the coverage, but still did not achieve its maximum the-
oretical coverage of 100%. The Ion AmpliSeq assay gen-
erated >99% coverage for some samples, but read depth
and coverage deteriorated rapidly in other samples, even
though the DNA input was sufficient. This deterioration
was a particular issue with one of the three primer pools
(primer pool 3), with the other two pools appearing to
perform better across all samples. We were unable to
determine the reason for this; it did not appear to be
related to amplicon length, GC content, primer length
or number of primers per pool. Perhaps a longer qPCR
assay more closely representing the amplicon size, which
was slightly longer than the GeneRead panel amplicons,
would be a better predictor of starting DNA input, but
this was not investigated further. For this reason we did
not continue to analyse all the available samples using
the Ion AmpliSeq panel after our initial evaluation of 24
samples as we predicted a higher failure rate for the
remaining sub-optimal samples. We also did not have
access to an Ion PGM or Ion Proton system and ancil-
lary devices to optimise the method on the recom-
mended instrument.
We were able to detect significant variants using both
the GeneRead and Ion AmpliSeq panels. All significant
variants found in an initial analysis were subject to re-
peat analysis starting from the original DNA extraction
to distinguish true positives from artefacts, as have been
described when analysing FFPE DNA using Sanger DNA
sequencing. We found a small number of variants thatcould not be replicated by NGS. As with Sanger DNA
sequencing, NGS is also affected by this underlying FFPE
DNA quality issue, possibly caused through DNA dam-
age due to deamination and cross-linking during forma-
lin fixation. This problem can be overcome by repeat
analysis starting from the original DNA, as the artefacts
are generally random in distribution [26]. Artefactual er-
rors were common in poorer quality DNA samples with
low input DNA amounts that typically had a higher
overall level of background noise, although there were
exceptions. These variants were also analysed by Sanger
DNA sequencing as a validation of the NGS method. In
this study, all the reproducible NGS BRCA significant var-
iants were confirmed using Sanger DNA sequencing, with
a single exception. This exception was due to limiting
amounts of DNA and problems developing a Sanger DNA
sequencing assay that would work on the highly degraded
DNA, rather than non-detection of the specific variant.
We performed a very limited evaluation of the poten-
tial false negative rate (i.e. BRCA mutations not detected
by the NGS assay). Full gene screens of BRCA 1 and
BRCA2 using a comparator method such as Sanger
DNA sequencing would not have been practical due to
limitations such as the time required to develop an assay
for DNA extracted from FFPE tumour tissue, and the
amount of DNA that would have been required to carry
out complete screens of both BRCA1 and BRCA2. How-
ever, all the known control samples with known BRCA
pathogenic variants were correctly identified (4 cell lines,
2 explants) and the comparison of the different panels
did not detect any additional mutations.
We detected 7 different pathogenic variants (in 8 sam-
ples) and 6 VUSs in BRCA1 and BRCA2 in our panel of
ovarian and breast samples. As we did not have access
to matched blood samples we were unable to determine
if any of these were somatic changes. There was no indi-
cation in the allele frequencies in any of the tumours to
suggest a low level somatic variant although this does
not rule out the possibility that these samples may have
a somatic variant at high level and be indistinguishable
from a typical germline variant in the tumour.
Further evaluation experiments were conducted with
the V.1 panel as this performed better on our samples,
to determine if the method was potentially able to detect
the low level variants one would predict to be seen in
tumour samples with somatic mutations with low neo-
plastic cell content. By admixing a FFPE sample contain-
ing a variant with a FFPE sample containing no mutant,
we were able to determine that an allele frequency of
about 5% was still detectable when the mean read depth
was >1,000x. Although we were aware of the variants
we were analysing, it seems reasonable to assume that
an allele frequency of down to 10% could be routinely
detected.
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a small number of samples, including all those with
BRCA significant variants and 3 without significant vari-
ants. When the optimal amount of DNA was added to
each plex (20 ng) the data were highly reproducible and
continued to generate comparable coverage statistics
until the DNA concentration fell below 1 ng.
Although the bioinformatics pipeline used, coupled
with visual inspection of the data, allowed us to evaluate
the results, it was not optimised or validated for routine
screening for BRCA mutations in tissue samples. Further
work would be required to develop a suitably rapid and
validated pipeline for routine analysis of such samples.
While the methods used were capable of effectively
detecting point mutations, it is important to note that
they have not been designed to detect large rearrange-
ments (genomic insertions or deletions). A significant
proportion of pathogenic BRCA1 and BRCA2 germline
mutations comprise large rearrangements in many popu-
lations [34,35], and a method suitable for use on FFPE
tissue would still be required to detect this class of mu-
tation. Multiplex ligation-dependent probe amplification
(MLPA) is commonly used in diagnostics to detect large
gene rearrangements in BRCA1 and BRCA2. Although
there is no reason per se why MLPA could not be used
to detect large rearrangements in FFPE tissue, there are
considerable challenges. In particular, any MLPA data
analysis method would need to be able to cope with gen-
omic instability in the tumour genome that may affect
the control probes used for data normalisation, as well
as being able to detect rearrangements present at low
level as somatic mutations.
The multiplex PCR panels described in this study have
relatively low amplicon tiling (low levels of overlapping
amplicons). This low level tiling, although efficient in
terms of reducing the complexity of the multiplex pri-
mer pools, increases the risk that specific amplicons will
fail to amplify due to an unknown variant (e.g. rare or
private germline variants) beneath the footprint of one
of the primers. Such events will lead to gaps in the read
coverage and thus increase the risk of false negative
results. As panel designs mature it would be interesting
to assess the effects of greater amplicon redundancy, for ex-
ample, aiming for coverage of every target base with at least
two amplicons (2x tiling) with different primer positions.
As the BRCA genes are tumour suppressors, two
events are required to completely knock out gene func-
tion. In cases of hereditary BRCA this second hit is
typically through loss of heterozygosity [36]. In tumour
samples both hits should be present, be they in BRCA-
mutated carriers or non-carriers if the tumour has
arisen due to BRCA loss of function. To identify tu-
mours with BRCA1 and BRCA2 inactivation that may
have the potential to respond to PARP inhibition,multiple technologies will be needed to detect the
various mechanisms of gene inactivation.
Conclusions
In conclusion, we have shown that mutation analysis of
BRCA1 and BRCA2 is feasible in DNA extracted from
FFPE tissue using an NGS approach. However, at present
this strategy should not be used as a substitute for com-
prehensive germline BRCA analysis in patients at high risk
of having a pathogenic BRCA1/2 variant, but could be
used to identify individuals with somatic only BRCA1/2
variants who may potentially benefit from PARP inhibition
therapy.
In addition, best practice guidelines for the analysis of
FFPE tumour [37], germline BRCA analysis [38] and
assay validation [39] should be followed, such as ensur-
ing significant findings can be replicated in order to en-
sure the results are reliable before adopting the practice
into a clinical diagnostics laboratory.
Additional files
Additional file 1: Sanger DNA sequencing PCR primers. Primer
sequences used to confirm results from BRCA postive samples.
Additional file 2: GeneRead V.1 panel coverage on control cell lines
and tumour explant samples. All unfixed control samples generated a
coverage of 97%, the theoretical maximum by design. One of the fixed
explant samples almost achieved maximum coverage while the other
was slightly below, possibly due to lower DNA quality in these fixed
samples.
Additional file 3: GeneRead V.1 panel read depth on control cell
lines and tumour explant samples. A mean read depth of >3,900 was
obtained for all samples. Regions of lower coverage are apparent in AZ01
(column 6, fixed explant) by the red and green horizontal lines not present
in the other samples. The thick red bar near the centre of the heatmap
indicates a region in the BRCA2 CDS not covered in the panel design.
Additional file 4: Effect on coverage and ability to detect variants
compared with DNA input. The coverage and percentage reads remained
consistent as DNA input was reduced. The BRCA2 c.10095delinsGAATTATATCT
p.(Ser3366AsnfsTer4) variant was still detectable at 2.5 ng total DNA input or
0.6 ng DNA input per primer pool.
Additional file 5: Consistency of percentage variant reads of SNPs.
The figure shows the effect on the percentage of variant reads relative to
DNA input. The percentage reads remain consistent across the four SNPs
in the regions of interest. The percentage read for rs1799950 is lower, but
consistently so.
Additional file 6: Comparison of GeneRead V.1 and V.2 coverage at
100x minimum depth and mean read depth. An overall improvement
in coverage and depth was observed with V.2, although the maximum
coverage by design (100%) was not achieved.
Additional file 7: Coverage at 100x minimum read depth and effect
on coverage at 25 and 30 PCR cycles. Coverage was better at
25 cycles for the majority of samples compared with 30 cycles.
Additional file 8: Summary of samples used in each method.
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